Track Hinge Health, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Hinge Health, Inc. HNGE · Stock Open Hinge Health, Inc. in new tab

120.99 USD
P/E
31.37
EPS
3.69
P/B
31.26
ROE
47.59
Target Price
135.38 USD
Hinge Health, Inc. logo

Hinge Health, Inc.

🧾 Earnings Recap – Q3 2026

Hinge Health reported 52% revenue growth and improved margins in Q3, while the stock rose 1.2%—a relatively muted reaction. The transcript highlights strong current profitability and early progress in new care programs, but provides limited detail here on the updated outlook.

  • Revenue was $235 million, up 52% year over year; last-12-month calculated billings increased 54% to $960 million.
  • Gross margin reached 88%, up about 480 basis points year over year. Operating income was $77 million, a 33% margin, up about 1,300 basis points.
  • Free cash flow, excluding one-time acquisition-related payments, was $120 million, or a 51% margin.
  • Early-access Migraine Care results included a 23% reduction in monthly migraine days; attacks were about five hours shorter on average, and roughly two-thirds of surveyed members improved their HIT-6 score.
  • The company described its planned GI Care offering and AI-enabled features, but the provided transcript ends before the full program details and updated financial guidance.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 9, 2027
P/E31.37
EPS3.69
Book Value3.70
Price to Book31.26
Debt/Equity11.32
% Insiders4.740%
Growth
Revenue Growth0.52%
Earnings Growth-0.68%
Estimates
Forward P/E35.56
Forward EPS3.26
Target Mean Price135.38

DCF valuation

Model fair value for Hinge Health, Inc. (HNGE)
Result
Sign in to run the valuation for HNGE.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
16 analysts · consensus Buy · mean target 135.38 USD (low 90.00, high 151.00) · as of 9 Nov 2026
Low 90.00
Mean 135.38
High 151.00
Price 120.99
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Hinge Health, Inc. Logo Hinge Health, Inc. Analysis (HNGE)

USA Official Website Stock

Is Hinge Health, Inc. a good investment? Hinge Health, Inc. (HNGE) is currently trading at 120.99 USD. Market analysts have a consensus price target of 135.38 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 31.37. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Hinge Health, Inc. is expected to release its next earnings report on Feb. 9, 2027. The market consensus estimate for Forward EPS is 3.26.

Investor FAQ

Does Hinge Health, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Hinge Health, Inc.?

Hinge Health, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 9, 2027. The company currently has a trailing EPS of 3.69.

Company Profile

Hinge Health, Inc. focuses on building a health system that scales and automates the delivery of care using technology. It designs its platform to address musculoskeletal system care (MSK), including acute injury, chronic pain, and post-surgical rehabilitation. The company also provides personalized and automated MSK care through AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device. It primarily serves self-insured employers. The company was founded in 2012 and is headquartered in San Francisco, California.

Exchange Ticker
US HNGE
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion